Back Hepatitis C

Hepatitis C

Over 1 Million People Have Been Treated with New Hepatitis Drugs, But Cost Remains a Barrier

More than 1 million people have now received hepatitis C treatment using the new highly effective and well-tolerated direct-acting antiviral agents despite their high cost, according to a report released this week by the World Health Organization. The Global Report on Access to Hepatitis C Treatment: Focus on Overcoming Barriers is available online.


New Triple Combo Cures Most DAA-Experienced and Hard-to-Treat Hepatitis C Patients Without Ribavirin

An investigational 3-drug coformulation from Gilead Sciences produced sustained virological response (SVR) in 95% to 97% of hard-to-treat hepatitis C patients in the Phase 3 POLARIS trials, including people who were previously treated with direct-acting antivirals and those with hepatitis C virus (HCV) genotype 3 and compensated cirrhosis, according to a recent company announcement. Gilead plans to request Food and Drug Administration approval of the new combination by the end of the year.


EASL Paris: AbbVie 3D Regimen for 8 Weeks Cures Almost All HCV Genotype 1b Patients

AbbVie's paritaprevir-based 3D regimen taken for just 8 weeks without ribavirin led to sustained virological response in 98% of easier-to-treat non-cirrhotic patients with hepatitis C virus (HCV) genotype 1b, according to findings from the GARNET study, presented last week at the EASL special conference New Perspectives in Hepatitis C Virus Infection - The Roadmap for Cure in Paris.


Response-Guided DAA Triple Regimen May Cure Hepatitis C in as Little as 3 Weeks

Response-guided therapy using 3 direct-acting antivirals without ribavirin cured a majority of easier-to-treat genotype 1b hepatitis C patients in just 3 weeks, according to results from a small pilot study published in the October 2016 edition of The Lancet Gastroenterology & Hepatology.


EASL Paris: 100% Cure Rate with AL-335, Odalasvir, and Simeprevir for 6 or 8 Weeks

A triple regimen containing 2 experimental hepatitis C drugs -- AL-335 and odalasvir -- plus simeprevir taken for either 6 or 8 weeks cured all previously untreated, non-cirrhotic patients with HCV genotype 1 in a small study, while a dual regimen without simeprevir cured 90%, according to findings presented last week at the EASL special conference New Perspectives in Hepatitis C Virus Infection - The Roadmap for Cure in Paris.


HIV Coinfection Not a Risk Factor for Liver Fibrosis Progression in People with Hepatitis C

HIV coinfection is not associated with accelerated progression of liver fibrosis in people with hepatitis C virus (HCV) infection, according to U.S. research published in the October 15 edition of the Journal of Infectious Diseases. Factors linked with fibrosis progression were low fibrosis stage at baseline and flares in alanine aminotransferase (ALT) levels.


STD 2016: HCV Infection and Reinfection Among Men Who Have Sex with Men

Public health officials in Michigan have identified a cluster of more than 20 cases of apparently sexually transmitted hepatitis C virus (HCV) infection among HIV-positive gay and bisexual men, according to a report at the 2016 STD Conference last week in Atlanta. Routine HCV screening at sexual health clinics can help detect more HCV infections among gay men, and prevention measures are needed to address the risk of HCV reinfection after spontaneous clearance or a cure, researchers concluded in recent related journal articles.


Coverage of 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016) coverage of the 5th International Symposium on Hepatitis Care in Substance Users (INHSU 2016), September 7-9 in Oslo, Norway.

Highlights include hepatitis C treatment for people who inject drugs and people in prison, extra-hepatic manifestations of hepatitis C, and development of an HCV vaccine.

INHSU 2016 coverage listing

INHSU 2016 website



EASL Issues New Hepatitis C Treatment Recommendations For All Genotypes

The European Association for the Study of the Liver (EASL) released its latest recommendations on treatment of hepatitis C at a special meeting last week in Paris. The updated guidelines now include highly effective interferon-free options for all hepatitis C virus (HCV) genotypes and for the most challenging patients.